Oscar Health (NYSE:OSCR) Receives "Equal Weight" Rating from Stephens

Key Points

• Stephens reaffirmed its “Equal Weight” rating on Oscar Health with a $34 price target, implying 5.45% upside from the prior close. Analysts’ overall consensus remains “Hold,” with an average target price of $29.90.
• Oscar Health reported quarterly EPS of $1.10, beating the $0.40 consensus estimate, while revenue rose 70.4% year over year to $4.88 billion.
• Insiders sold 4.32 million shares worth approximately $126.8 million over the past three months, including substantial sales by Director Mario Schlosser and CEO Mark Bertolini under pre-arranged trading plans.

Oscar Health (NYSE:OSCR - Get Free Report)'s stock had its "equal weight" rating reissued by equities researchers at Stephens in a research note issued on Thursday, Benzinga reports. They presently have a $34.00 price objective on the stock. Stephens' price target suggests a potential upside of 5.45% from the stock's previous close.

Several other analysts also recently weighed in on OSCR. Piper Sandler reiterated an "overweight" rating on shares of Oscar Health in a report on Thursday. Bank of America restated an "underperform" rating and set a $30.00 price target on shares of Oscar Health in a research report on Thursday. Barclays lifted their price objective on Oscar Health from $39.00 to $49.00 and gave the company an "overweight" rating in a research note on Thursday. Wall Street Zen raised Oscar Health from a "buy" rating to a "strong-buy" rating in a research note on Sunday, June 14th. Finally, Zacks Research upgraded Oscar Health from a "hold" rating to a "strong-buy" rating in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $29.90.

Oscar Health Trading Down 0.6%

NYSE OSCR opened at $32.24 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.09 and a quick ratio of 1.09. The stock has a market capitalization of $9.95 billion, a P/E ratio of 23.03, a PEG ratio of 0.48 and a beta of 2.37. The firm's 50-day moving average is $30.70 and its two-hundred day moving average is $23.83. Oscar Health has a 12 month low of $10.69 and a 12 month high of $34.48.

Oscar Health (NYSE:OSCR - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.10 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.70. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The business had revenue of $4.88 billion during the quarter, compared to analysts' expectations of $4.73 billion. During the same period last year, the business earned ($0.89) earnings per share. The business's revenue for the quarter was up 70.4% on a year-over-year basis. On average, sell-side analysts anticipate that Oscar Health will post 1.54 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mario Schlosser sold 880,000 shares of the business's stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $29.38, for a total transaction of $25,854,400.00. Following the completion of the transaction, the director directly owned 480,866 shares of the company's stock, valued at $14,127,843.08. The trade was a 64.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Mark Bertolini sold 624,244 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $28.48, for a total value of $17,778,469.12. Following the completion of the sale, the chief executive officer directly owned 7,751,570 shares in the company, valued at $220,764,713.60. This represents a 7.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 4,322,257 shares of company stock valued at $126,818,346 in the last three months. 22.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oscar Health

A number of large investors have recently modified their holdings of the company. CoreCap Advisors LLC lifted its position in shares of Oscar Health by 526.3% during the 2nd quarter. CoreCap Advisors LLC now owns 1,190 shares of the company's stock worth $34,000 after purchasing an additional 1,000 shares during the last quarter. GAMMA Investing LLC increased its holdings in Oscar Health by 32.9% in the second quarter. GAMMA Investing LLC now owns 1,441 shares of the company's stock valued at $41,000 after buying an additional 357 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in Oscar Health in the second quarter valued at $57,000. Allworth Financial LP raised its stake in Oscar Health by 124.9% in the second quarter. Allworth Financial LP now owns 2,031 shares of the company's stock valued at $58,000 after buying an additional 1,128 shares in the last quarter. Finally, IFP Advisors Inc lifted its holdings in Oscar Health by 69.5% during the 2nd quarter. IFP Advisors Inc now owns 2,139 shares of the company's stock worth $61,000 after buying an additional 877 shares during the last quarter. 75.70% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Oscar Health raised its full-year 2026 earnings outlook and improved its expected medical loss ratio, suggesting better-than-anticipated cost control and profitability. The company maintained its revenue outlook, reducing concerns that the earnings improvement depends solely on weaker growth. Oscar Health Raises FY Earnings Guidance Ahead of Investor Day
• Positive Sentiment: Management plans a major ACA expansion over the next three years, indicating confidence in Oscar’s ability to gain members and extend its market position. Investors appear encouraged that the growth initiative is being paired with improving medical-cost performance. Oscar Health Plans Major Obamacare Expansion Over Next Three Years
• Positive Sentiment: Zacks added OSCR to its Rank #1, or “Strong Buy,” list of growth stocks, providing additional momentum and favorable external validation. Best Growth Stocks to Buy for September 17th
• Neutral Sentiment: Robert W. Baird raised its price target from $27 to $33 but kept a Neutral rating. With the target only modestly above the referenced $32.24 price, the call supports the valuation while signaling limited near-term upside. Baird Raises Oscar Health Price Target
• Negative Sentiment: A comparison with Centene favored Oscar’s rival because of Centene’s diversification, cash generation and recent share gains. Commentary also noted that Oscar is pursuing growth in a potentially shrinking ACA market, creating execution and pricing risks. Oscar Health vs. Centene

About Oscar Health

Oscar Health, Inc is a technology-focused health insurance company that offers health plans and related services to individuals, families and small businesses in the United States. The company's primary business is providing Individual and Family plans through the Affordable Care Act marketplaces, along with health insurance options for small-group employers in select markets.

Oscar combines insurance coverage with digital tools designed to help members manage their care. Its offerings include online and mobile enrollment, virtual care, provider search and navigation services, claims and benefits information, and access to care teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.